<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://danielzickler.com/wp-content/themes/getnoticed/inc/feeds/style.xsl" type="text/xsl" media="screen"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
xmlns:podcast="https://podcastindex.org/namespace/1.0"
xmlns:rawvoice="https://blubrry.com/developer/rawvoice-rss/"
>

<channel>
	<title>Daniel Zickler, MDEnglish | Daniel Zickler, MD</title>
	<atom:link href="https://danielzickler.com/category/english/feed" rel="self" type="application/rss+xml" />
	<link>https://danielzickler.com</link>
	<description>Medicine with Passion</description>
	<lastBuildDate>Fri, 13 Nov 2026 19:46:56 +0000</lastBuildDate>
	<language>de</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	

<image>
	<url>https://i0.wp.com/danielzickler.com/wp-content/uploads/2026/11/dz-website-icon-512.png?fit=32%2C32&#038;ssl=1</url>
	<title>English | Daniel Zickler, MD</title>
	<link>https://danielzickler.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<atom:link rel="hub" href="https://pubsubhubbub.appspot.com/" />
	<itunes:new-feed-url>http://danielzickler.com/feed/podcast</itunes:new-feed-url>
	<itunes:author>English &#8211; Daniel Zickler, MD</itunes:author>
	<itunes:explicit>false</itunes:explicit>
	<itunes:image href="http://danielzickler.com/wp-content/uploads/powerpress/mwp2.jpg" />
	<itunes:type>episodic</itunes:type>
	<itunes:owner>
		<itunes:name>English &#8211; Daniel Zickler, MD</itunes:name>
		<itunes:email>daniel@danielzickler.com</itunes:email>
	</itunes:owner>
	<podcast:medium>podcast</podcast:medium>
	<image>
		<title>English | Daniel Zickler, MD</title>
		<url>http://danielzickler.com/wp-content/uploads/powerpress/mwp2.jpg</url>
		<link>https://danielzickler.com/category/english</link>
	</image>
	<itunes:category text="Education" />
	<rawvoice:rating>TV-G</rawvoice:rating>
	<podcast:podping usesPodping="true" />
	<rawvoice:subscribe feed="https://danielzickler.com/category/english/feed" html="https://danielzickler.com/about-2" itunes="https://itunes.apple.com/de/podcast/medicine-passion-podcast-episode-1-neue-skills-erlernen/id1013487155?i=1000427891318&amp;mt=2&amp;app=podcast" tunein="http://danielzickler.com/feed/podcast" spotify="https://open.spotify.com/show/6QM3ukJ1g5kV9wK1lqcxTC"></rawvoice:subscribe>
<site xmlns="com-wordpress:feed-additions:1">57948792</site>		<item>
		<title>Does Pelacarsen Prevent Heart Attack and Stroke in Patients with High Lipoprotein(a)?</title>
		<link>https://danielzickler.com/does-pelacarsen-prevent-heart-attack-and-stroke-in-patients-with-high</link>
		<comments>https://danielzickler.com/does-pelacarsen-prevent-heart-attack-and-stroke-in-patients-with-high#respond</comments>
		<pubDate>Fri, 13 Nov 2026 07:48:43 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[English]]></category>
		<category><![CDATA[Nephrologie]]></category>
		<guid isPermaLink="false">https://danielzickler.com/?p=2369</guid>

				<description><![CDATA[Diesen Beitrag gibt es auch auf Deutsch. About one in five people worldwide has a lipoprotein(a) level above 50 mg/dl, an estimated 1.4 billion people according to the authors. The level is largely genetically determined, and diet, exercise or statins barely change it. Genetic and epidemiological studies suggest high Lp(a) contributes causally to atherosclerosis and [&#8230;]]]></description>
					<content:encoded><![CDATA[<p><em>Diesen Beitrag gibt es auch <a href="https://danielzickler.com/?p=2366">auf Deutsch</a>.</em></p><a href="https://danielzickler.com/does-pelacarsen-prevent-heart-attack-and-stroke-in-patients-with-high"></a>
<p>About one in five people worldwide has a lipoprotein(a) level above 50 mg/dl, an estimated 1.4 billion people according to the authors. The level is largely genetically determined, and diet, exercise or statins barely change it. Genetic and epidemiological studies suggest high Lp(a) contributes causally to atherosclerosis and aortic valve stenosis. The obvious question: does targeted lowering prevent heart attacks and strokes?</p>
<p><span id="more-2369"></span></p>
<p>Lp(a)HORIZON is the first large outcomes trial to test this. The results are now published in the New England Journal of Medicine.</p>
<h2>Study design</h2>
<p>Pelacarsen is an antisense oligonucleotide inhibiting hepatic production of apolipoprotein(a). The double-blind, placebo-controlled trial ran at 797 sites in 42 countries. Patients aged 18 to 80 qualified with a myocardial infarction, ischaemic stroke or symptomatic peripheral artery disease between 3 months and 10 years earlier and an Lp(a) of at least 70 mg/dl. Before randomisation, secondary prevention was optimised according to guidelines over 30 to 90 days. Patients then received 80 mg pelacarsen subcutaneously or placebo every month.</p>
<p>The primary endpoint was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or urgent coronary revascularisation. The subgroup with Lp(a) of 90 mg/dl or higher was analysed separately.</p>
<p>8322 patients were analysed. Mean age was 59.7 years, 27.0% were women and 76.6% had a prior myocardial infarction. Median Lp(a) was 236 nmol/l. Risk factors were well controlled: median LDL 64.6 mg/dl, mean systolic blood pressure 125 mmHg, and 77.6% were on high-intensity statin therapy.</p>
<h2>Results</h2>
<p>Pelacarsen lowered Lp(a) as planned. At 12 months, the median was 64.4 nmol/l versus 233.4 nmol/l on placebo, a reduction of 78.4% versus 3.2%. Averaged over the entire trial, the reduction was 73.9%. LDL fell by an additional 11.3 percentage points compared with placebo.</p>
<p>There was no clinical benefit. After a median of 4.7 years, the primary endpoint occurred in 511 patients (12.3%) on pelacarsen and 503 patients (12.1%) on placebo. The hazard ratio was 1.02 (95% CI 0.90 to 1.15, p = 0.76). In the subgroup at 90 mg/dl or above, the rate was 12.3% in both groups (HR 1.00, 95% CI 0.87 to 1.15). Narrower endpoints, individual components and all-cause death (5.7% vs 5.9%) did not differ either. No prespecified subgroup showed a difference.</p>
<h2>Safety</h2>
<p>Serious adverse events were less frequent on pelacarsen (37.3% vs 41.1%). Milder side effects were much more common. Influenza-like reactions occurred in 31.9% versus 5.8%, injection-site reactions in 25.6% versus 2.9%. 20.6% versus 7.5% permanently stopped treatment because of adverse events. Anaphylaxis was confirmed in 19 patients on pelacarsen and none on placebo. Eight hypersensitivity reactions led to hospitalisation, none were fatal. After a suspected case in March 2023, injections had to be given under medical supervision for six months.</p>
<h2>How the authors interpret the result</h2>
<p>The authors offer two explanations. First, genetic studies describe lifelong low Lp(a), whereas the trial lowered it for a few years. The two are not equivalent. Second, LDL and blood pressure were far better controlled than in the genetic cohorts. With such strong background therapy, little room may remain for an additional effect. The authors do not consider the COVID-19 pandemic responsible, since Lp(a) lowering matched expectations from the phase 2 trial.</p>
<h2>Limitations</h2>
<p>Patients were mostly male and White. With 35.1%, almost twice as many patients stopped pelacarsen early as stopped placebo (18.3%). This shortens actual treatment exposure and may bias the result. Only secondary prevention was studied, not patients without a prior event or immediately after acute coronary syndrome. The manufacturer funded the trial and designed it together with an academic research centre. Five authors are employees of the manufacturer.</p>
<h2>What comes next</h2>
<p>Further Lp(a)-lowering agents are in phase 3 outcome trials. They lower Lp(a) more, by over 90% or about 85%, enrol patients with higher baseline levels and in part also test primary prevention. Whether they reach a different result is open.</p>
<h2>What this means for practice</h2>
<p>Lp(a)HORIZON is a clear negative result from a large trial with complete follow-up.</p>
<ol>
<li>Elevated Lp(a) remains a risk marker. This trial does not show lowering it prevents events.</li>
<li>A lower lab value is not a lower risk. A reduction of almost 80% makes this plain.</li>
<li>In patients with high Lp(a), consistent control of the other risk factors remains what is proven to help.</li>
</ol>
<p>I am happy to discuss how you handle elevated Lp(a) in your patients on LinkedIn.</p>
<p><em>Source: Cho L, Nicholls SJ, Frndak S, et al., Nissen SE, for the Lp(a)HORIZON Investigators. Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). N Engl J Med, online 7 Nov 2026. doi:10.1056/NEJMoa2610159. ClinicalTrials.gov NCT04023552.</em></p>
<hr />
<p><small>Source: DOI: <a href="https://doi.org/10.1056/NEJMoa2610159">10.1056/NEJMoa2610159</a> · <a href="https://doi.org/10.1056/NEJMoa2610159">Original article</a></small></p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/does-pelacarsen-prevent-heart-attack-and-stroke-in-patients-with-high/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">2369</post-id>	</item>
		<item>
		<title>Does the Anti-Inflammatory Antibody Ziltivekimab Prevent Heart Attack and Stroke in Chronic Kidney Disease?</title>
		<link>https://danielzickler.com/does-the-anti-inflammatory-antibody-ziltivekimab-prevent-heart-attack</link>
		<comments>https://danielzickler.com/does-the-anti-inflammatory-antibody-ziltivekimab-prevent-heart-attack#respond</comments>
		<pubDate>Thu, 12 Nov 2026 19:36:17 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[English]]></category>
		<category><![CDATA[Nephrologie]]></category>
		<guid isPermaLink="false">https://danielzickler.com/?p=2361</guid>

				<description><![CDATA[Diesen Beitrag gibt es auch auf Deutsch. Patients with chronic kidney disease face a high risk of heart attack and stroke, even with well-controlled cholesterol and blood pressure. Part of this residual risk has long been attributed to chronic inflammation. CRP and interleukin-6 are often elevated in kidney disease and predict events. The idea is [&#8230;]]]></description>
					<content:encoded><![CDATA[<p><em>Diesen Beitrag gibt es auch <a href="https://danielzickler.com/?p=2358">auf Deutsch</a>.</em></p><a href="https://danielzickler.com/does-the-anti-inflammatory-antibody-ziltivekimab-prevent-heart-attack"></a>
<p>Patients with chronic kidney disease face a high risk of heart attack and stroke, even with well-controlled cholesterol and blood pressure. Part of this residual risk has long been attributed to chronic inflammation. CRP and interleukin-6 are often elevated in kidney disease and predict events. The idea is obvious: lower inflammation, lower risk.</p>
<p><span id="more-2361"></span></p>
<p>The ZEUS trial, now published in the New England Journal of Medicine, put this idea to the test.</p>
<h2>Why interleukin-6</h2>
<p>Several lines of evidence pointed to interleukin-6. Genetic variants weakening signalling through the interleukin-6 receptor are associated with less atherosclerosis. In CANTOS, an antibody against interleukin-1β reduced cardiovascular events, and the effect grew with the reduction in downstream interleukin-6. In the phase 2 RESCUE trial, ziltivekimab substantially lowered CRP in patients with chronic kidney disease.</p>
<h2>Study design</h2>
<p>ZEUS was a double-blind, placebo-controlled, event-driven trial at 757 sites in 38 countries. Adults qualified with three features: established atherosclerotic disease, chronic kidney disease (eGFR 15 to below 60 ml/min/1.73 m², or eGFR of 60 or more with a urinary albumin-to-creatinine ratio of at least 200 mg/g), and high-sensitivity CRP of at least 2 mg/l. They received 15 mg ziltivekimab subcutaneously once a month or placebo.</p>
<p>The primary endpoint was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. The trial was powered at 95% to detect a 20% relative reduction.</p>
<p>6376 patients were analysed. Mean age was 69.4 years and 27.5% were women. 65.8% had diabetes and 42.2% heart failure. Mean eGFR was 44.5, median CRP 4.5 mg/l and median LDL 71 mg/dl. 92.6% were already on lipid-lowering therapy.</p>
<h2>Results</h2>
<p>Biologically, ziltivekimab worked. At 24 months, the reduction in free interleukin-6 exceeded placebo by 76 percentage points and the reduction in CRP by 64 percentage points.</p>
<p>Clinically, there was no benefit. After a median of 33 months, the primary endpoint occurred in 561 of 3184 patients (17.6%) on ziltivekimab and 565 of 3192 (17.7%) on placebo. The hazard ratio was 0.99 (95% CI 0.88 to 1.11, p = 0.84). With 1126 events, the trial exceeded the planned 1044.</p>
<p>Secondary endpoints were equally balanced. Cardiovascular death 11.1% versus 11.2%, all-cause death 16.9% versus 17.0% (HR 0.99). The composite kidney endpoint of eGFR decline of at least 40%, kidney failure or cardiovascular death occurred in 20.2% versus 19.3% (HR 1.05, 95% CI 0.94 to 1.17).</p>
<h2>Safety</h2>
<p>Serious adverse events were equally frequent at 54.6% versus 54.8%. The details differ. Serious infections occurred in 20.4% versus 17.9%, deaths from infection in 3.2% versus 2.5%. Cellulitis was more frequent (2.9% vs 1.0%), as was sepsis (1.9% vs 1.3%). Serious venous thromboembolism occurred in 1.6% versus 0.6%, serious haemorrhage in 5.1% versus 4.0%. Platelet counts below 100,000/µl were seen in 7.4% versus 3.2%. The authors explain the excess of thromboembolism only partly by known risk factors.</p>
<h2>How the authors interpret the result</h2>
<p>The authors discuss four explanations. First, disease in ZEUS was more advanced than in CANTOS: patients were on average ten years older, the placebo event rate was 6.8 instead of 4.5 per 100 person-years, and mortality 6.2 instead of 3.0. Second, only inhibition further upstream, at interleukin-1β or the inflammasome, might work. Third, the genetic data point to the interleukin-6 receptor, whereas ziltivekimab binds the cytokine itself. A receptor blocker might act differently. Fourth, CRP might not be the right marker to select patients with modifiable inflammatory risk.</p>
<h2>Limitations</h2>
<p>A mean treatment exposure of 33 months is short for atherosclerosis, and 14% of patients did not adhere to treatment. Few women were enrolled. The findings apply to ziltivekimab in this population and do not transfer to receptor blockers or other patient groups. The manufacturer funded and ran the trial and analysed the data, with independent verification at an academic centre. Seven authors are employees of the manufacturer. Two further ziltivekimab trials are ongoing, in heart failure with preserved ejection fraction and in acute coronary syndrome.</p>
<h2>What this means for practice</h2>
<p>ZEUS is a clear negative result from a large, well-conducted trial. For patients with chronic kidney disease and atherosclerosis, treatment does not change.</p>
<ol>
<li>Elevated CRP remains a risk marker. As a treatment target in kidney patients, this trial does not support it.</li>
<li>A lowered biomarker does not replace a clinical endpoint. ZEUS shows this clearly: strong effect in the lab, no effect on patients.</li>
<li>Anti-inflammatory treatment comes at a price. More infections and thromboembolism weigh heavily in multimorbid kidney patients.</li>
</ol>
<p>I am happy to discuss how you view inflammation as a target in your kidney patients on LinkedIn.</p>
<p><em>Source: Ridker PM, Lincoff AM, Marx N, et al., Perkovic V, for the ZEUS Investigators. Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease. N Engl J Med, online 7 Nov 2026. doi:10.1056/NEJMoa2612126. ClinicalTrials.gov NCT05021835.</em></p>
<hr>
<p><small>Source: DOI: <a href="https://doi.org/10.1056/NEJMoa2612126">10.1056/NEJMoa2612126</a> &middot; <a href="https://doi.org/10.1056/NEJMoa2612126">Original article</a></small></p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/does-the-anti-inflammatory-antibody-ziltivekimab-prevent-heart-attack/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">2361</post-id>	</item>
		<item>
		<title>Prepare for Dialysis or Choose Conservative Care? What the First Randomised Trial in Older People with Kidney Failure Shows</title>
		<link>https://danielzickler.com/prepare-for-dialysis-or-choose-conservative-care-what-the-first-random</link>
		<comments>https://danielzickler.com/prepare-for-dialysis-or-choose-conservative-care-what-the-first-random#respond</comments>
		<pubDate>Thu, 12 Nov 2026 19:05:41 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[English]]></category>
		<category><![CDATA[Nephrologie]]></category>
		<guid isPermaLink="false">https://danielzickler.com/?p=2335</guid>

				<description><![CDATA[Diesen Beitrag gibt es auch auf Deutsch. An 83-year-old man with an eGFR of 12, heart failure and diabetes sits in clinic. The question is familiar: create a fistula and prepare for dialysis, or continue conservative care focused on symptoms and quality of life? Until now, this decision rested on observational data. A 2025 Cochrane [&#8230;]]]></description>
					<content:encoded><![CDATA[<p><em>Diesen Beitrag gibt es auch <a href="https://danielzickler.com/?p=2326">auf Deutsch</a>.</em></p><a href="https://danielzickler.com/prepare-for-dialysis-or-choose-conservative-care-what-the-first-random"></a>
<p>An 83-year-old man with an eGFR of 12, heart failure and diabetes sits in clinic. The question is familiar: create a fistula and prepare for dialysis, or continue conservative care focused on symptoms and quality of life? Until now, this decision rested on observational data. A 2025 Cochrane review found 23 such studies and rated the certainty of evidence as very low throughout. The groups differed too much for a fair comparison.</p>
<p><span id="more-2335"></span></p>
<p>Prepare for Kidney Care, published in The Lancet, is the first randomised trial on this question.</p>
<h2>Who was included</h2>
<p>The trial ran in 31 kidney centres across England, Wales, Scotland and Northern Ireland. Patients had an eGFR below 15 ml/min/1.73 m², confirmed by a second value within the previous year. They had to be 80 or older, or aged 65 to 79 with frailty (WHO performance status 3 or higher) or multimorbidity (Davies comorbidity score 2 or higher). Patients judged unfit for dialysis, expected to need dialysis within four weeks, or planning transplantation were excluded.</p>
<p>445 patients were randomised. Median age was 82 years, median eGFR 13. Three quarters were 80 or older, and almost half had diabetes.</p>
<h2>Two strategies, no obligation to dialyse</h2>
<p>The trial compared two care pathways, not two treatments. One arm prepared for dialysis: information on modalities, choice of modality, access creation, and dialysis start once kidney function and symptoms suggested it. The other arm followed a protocolised conservative pathway called responsive management. It included a comprehensive assessment with advance care planning, usually at home, monthly phone calls, annual home visits and extra appointments as needed. Both arms ended in palliative care according to local routine.</p>
<p>The primary outcome was quality-adjusted life-years (QALYs), combining survival with the EQ-5D-5L, measured every four months. A patient co-applicant shaped this choice, because length and quality of life matter equally to people with kidney failure.</p>
<h2>Results</h2>
<p>After a mean follow-up of 4.5 years, QALYs were 1.354 with conservative care and 1.472 with dialysis preparation. The adjusted difference was −0.147 (95% CI −0.350 to 0.056, p = 0.16), equivalent to about 78 days at a quality of life of 0.69. The prespecified minimal clinically important difference was 0.345 QALYs. Neither strategy was superior.</p>
<p>Mortality did not differ significantly (adjusted hazard ratio 1.10, 95% CI 0.87 to 1.40). 69% died in the conservative arm and 63% in the dialysis arm. Hospital-free days, place of death, symptom burden, treatment burden and physical function were similar.</p>
<p>EQ-5D-5L scores were slightly lower in the conservative arm (difference −0.039, 95% CI −0.074 to −0.005). The authors consider this unlikely to be clinically important.</p>
<p>Dialysis access complications were less frequent with conservative care: 3.74 versus 11.33 events per 100 patient-years (adjusted rate ratio 0.41, 95% CI 0.19 to 0.88). This outcome was defined as a harm only during peer review and rests on 74 events in 36 patients.</p>
<h2>The number to remember</h2>
<p>In the dialysis arm, only 60 of 217 patients (28%) started dialysis, at a median of 394 days. In the conservative arm, 42 of 228 (18%) did. Annual mortality was 25 to 30%. In this population, the risk of death far exceeded the risk of needing dialysis.</p>
<p>In practice, many access procedures in this group are never used. Kidney function stabilises, or another illness determines the course.</p>
<h2>Limitations</h2>
<p>The trial tested superiority. It does not prove equivalence or non-inferiority. It was open-label, and outcomes were not assessed blind. About one in four patients switched pathways (28% and 25%), which dilutes differences between arms. The per-protocol analysis showed a slightly larger difference but supported the main result.</p>
<p>Of 1,261 eligible patients approached, 445 agreed to randomisation. People who accept random allocation might differ from those who decline. 91% of participants were White, more than among new dialysis patients of similar age in the UK. Men had lower QALYs with conservative care than women, but this analysis was not prespecified and lacked power. Part of the trial fell into the COVID-19 pandemic. The results reflect UK care, where conservative kidney management is established.</p>
<p>The trial was funded by the UK National Institute for Health and Care Research. Some authors report travel support, speaker fees or employment with companies in pharma and data analytics, unrelated to this work.</p>
<h2>What this means for practice</h2>
<p>Dialysis preparation as the automatic default for people over 80 and frail older patients is hard to justify on this evidence. Conservative care is an equal option and deserves to be offered actively, not only when a patient declines dialysis.</p>
<ol>
<li>Raise the conservative option early and explicitly, with concrete numbers instead of general prognoses.</li>
<li>Weigh access surgery against the likelihood of ever using it.</li>
<li>Revisit decisions regularly. One in four patients changed their mind during the trial.</li>
<li>Organise conservative care as active care, with regular contact, symptom control and advance care planning.</li>
</ol>
<p>I am happy to discuss how these conversations work in your centre on LinkedIn.</p>
<p><em>Source: Caskey FJ, Worthington J, Liu Y et al., Lane JA. Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care): a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial. Lancet, online 4 Nov 2026. doi:10.1016/S0140-6736(26)01818-0. ISRCTN17133653.</em></p>
<hr />
<p><small>Source: DOI: <a href="https://doi.org/10.1016/S0140-6736(26)01818-0">10.1016/S0140-6736(26)01818-0</a> · <a href="https://doi.org/10.1016/S0140-6736(26)01818-0">Original article</a></small></p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/prepare-for-dialysis-or-choose-conservative-care-what-the-first-random/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">2335</post-id>	</item>
		<item>
		<title>ECMO at the Scene: Does Prehospital ECPR Improve Survival in Young Patients with Refractory Cardiac Arrest?</title>
		<link>https://danielzickler.com/ecmo-at-the-scene-does-prehospital-ecpr-improve-survival-in-young-pati</link>
		<comments>https://danielzickler.com/ecmo-at-the-scene-does-prehospital-ecpr-improve-survival-in-young-pati#respond</comments>
		<pubDate>Thu, 12 Nov 2026 19:05:24 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[English]]></category>
		<category><![CDATA[Intensivmedizin]]></category>
		<guid isPermaLink="false">https://danielzickler.com/?p=2340</guid>

				<description><![CDATA[Diesen Beitrag gibt es auch auf Deutsch. A 44-year-old man collapses in the street, ventricular fibrillation, bystanders start CPR at once. After 20 minutes and several shocks there is still no return of spontaneous circulation. Extracorporeal cardiopulmonary resuscitation (ECPR) with venoarterial ECMO is the last option for such patients. So far, it almost always means [&#8230;]]]></description>
					<content:encoded><![CDATA[<p><em>Diesen Beitrag gibt es auch <a href="https://danielzickler.com/?p=2330">auf Deutsch</a>.</em></p><a href="https://danielzickler.com/ecmo-at-the-scene-does-prehospital-ecpr-improve-survival-in-young-pati"></a>
<p>A 44-year-old man collapses in the street, ventricular fibrillation, bystanders start CPR at once. After 20 minutes and several shocks there is still no return of spontaneous circulation. Extracorporeal cardiopulmonary resuscitation (ECPR) with venoarterial ECMO is the last option for such patients. So far, it almost always means transport with ongoing chest compressions to an ECMO centre and cannulation there.</p>
<p><span id="more-2340"></span></p>
<p>The Dutch OnScene study brought ECMO to the patient instead, by helicopter.</p>
<h2>Why the question was open</h2>
<p>Three randomised trials tested in-hospital ECPR. ARREST showed better survival to discharge in a single, highly experienced centre. The Prague Hyperinvasive trial found no higher rate of good neurological outcome at six months. INCEPTION, multicentre and also Dutch, showed no survival benefit. All three shared long arrest times: a median of 59, 60 and 74 minutes. Since arrest duration strongly determines survival, the obvious question was whether ECPR simply came too late.</p>
<h2>Study design</h2>
<p>OnScene was a nationwide, nonrandomised study with a stepped-wedge design. All four Dutch helicopter stations started between October 2021 and June 2022 without ECMO on board and switched to ECMO on board one after another. The analysis followed intention to treat: what counted was whether the team could offer ECPR at the time of the call, not whether it actually cannulated.</p>
<p>Eligible patients were 18 to 50 years old with an initial shockable rhythm or pulseless electrical activity with suspected pulmonary embolism. The arrest had to be witnessed or show signs of life and last more than 20 minutes after helicopter dispatch. Exclusions included end-tidal CO2 below 1.2 kPa and an expected arrival at an ECMO centre within 30 minutes. Cannulation was performed by helicopter physicians, anaesthesiologists and trauma surgeons, after a structured training programme.</p>
<p>Of 3,362 dispatches, 231 patients remained: 144 in the ECPR phase and 87 in the conventional phase. Median age was 44 years in both groups.</p>
<h2>Results</h2>
<p>57 of 144 patients (40%) in the ECPR phase and 17 of 87 (20%) in the conventional phase survived to discharge. The odds ratio was 2.72 (95% CI 1.59 to 4.66, p = 0.002), adjusted 2.66 (1.56 to 4.55). A good neurological outcome (CPC 1 or 2) at six months was seen in 36% versus 13% (OR 4.22, 95% CI 2.82 to 6.32).</p>
<p>The time gain was large. Median time to ECMO flow was 45 minutes with prehospital cannulation and 77 minutes with in-hospital cannulation. From helicopter arrival to flow took 27 instead of 64 minutes.</p>
<p>Not every patient in the ECPR phase was cannulated. An attempt was made in 98 of 144 (68%). 32 patients regained spontaneous circulation first, and in 11 the femoral vessels were not visible on ultrasound. In the conventional phase, 24 patients received in-hospital ECPR.</p>
<h2>Safety</h2>
<p>Cannulation failed in 15 of 98 prehospital attempts (15%) and in 4 of 24 in-hospital attempts (17%), in line with published in-hospital ECPR data. Bleeding and cannula-site infections occurred at similar rates. In total, 32 adverse events were reported in the ECPR phase and 11 in the conventional phase.</p>
<h2>Limitations</h2>
<p>The main limitation is the design. Without randomisation, selection effects remain possible. The rhythm distribution shows this: 89% had ventricular fibrillation or tachycardia in the ECPR phase versus 75% in the conventional phase. Pulmonary embolism as the cause was more frequent in the conventional phase (23% versus 11%). Adjusting for rhythm did not materially change the result, and the difference persisted among patients with shockable rhythms (42% versus 25%, post hoc).</p>
<p>The order of the helicopter stations was not randomised. 390 patients were planned and 231 enrolled, because recruitment was slower than expected. Neurological outcome was assessed by a single unblinded intensivist. The direct comparison of prehospital with in-hospital ECPR (35% versus 25% survival) rests on small numbers and no random allocation.</p>
<p>The findings apply only to comparable systems: young patients, a helicopter network reaching almost the entire country within 30 minutes, and physicians with a dedicated training programme. The study was funded by the Dutch Ministry of Health. Author disclosures are available online from the journal and are not part of the article text.</p>
<h2>What this means for practice</h2>
<p>OnScene provides the first prospective comparison for prehospital ECPR, not randomised proof. The message is still clear: ECPR is time-critical, and the time gain depends on the system, not on a single centre.</p>
<ol>
<li>In refractory arrest with a shockable rhythm, consider ECPR early, not after 40 minutes.</li>
<li>Know your own times: how long does it take in your region from collapse to ECMO flow?</li>
<li>Plan an ECPR programme as a chain, from dispatch through cannulation to intensive care.</li>
</ol>
<p>I am happy to discuss how ECPR pathways are organised in your region on LinkedIn.</p>
<p><em>Source: Reis Miranda D, Moors X, Ali S, et al., Gommers D. Prehospital Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest. N Engl J Med, online 7 Nov 2026. doi:10.1056/NEJMoa2602919. ClinicalTrials.gov NCT04620070.</em></p>
<hr />
<p><small>Source: DOI: <a href="https://doi.org/10.1056/NEJMoa2602919">10.1056/NEJMoa2602919</a> · <a href="https://doi.org/10.1056/NEJMoa2602919">Original article</a></small></p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/ecmo-at-the-scene-does-prehospital-ecpr-improve-survival-in-young-pati/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">2340</post-id>	</item>
		<item>
		<title>Maximizing Productivity in Medicine: 4 Essential Strategies</title>
		<link>https://danielzickler.com/maximizing-productivity-in-medicine-4-essential-strategies</link>
		<comments>https://danielzickler.com/maximizing-productivity-in-medicine-4-essential-strategies#respond</comments>
		<pubDate>Sat, 04 May 2024 20:00:13 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[Career]]></category>
		<category><![CDATA[Communication]]></category>
		<category><![CDATA[English]]></category>
		<guid isPermaLink="false">https://danielzickler.com/?p=1972</guid>

				<description><![CDATA[In the fast-paced world of medicine, productivity isn&#8217;t just desirable; it&#8217;s essential for delivering quality patient care, conducting research, and managing administrative tasks. Here are four key strategies to enhance productivity in the medical field: Effective Time Management: With numerous responsibilities competing for attention, mastering time management is crucial. Prioritize tasks based on urgency and [&#8230;]]]></description>
					<content:encoded><![CDATA[<p>In the fast-paced world of medicine, productivity isn&#8217;t just desirable; it&#8217;s essential for delivering quality patient care, conducting research, and managing administrative tasks. Here are four key strategies to enhance productivity in the medical field:</p><a href="https://danielzickler.com/maximizing-productivity-in-medicine-4-essential-strategies"><img width="760" height="507" src="https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?fit=760%2C507&amp;ssl=1" class="featured-image wp-post-image" alt="Unsplash" srcset="https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?w=2560&amp;ssl=1 2560w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?resize=300%2C200&amp;ssl=1 300w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?resize=1024%2C683&amp;ssl=1 1024w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?resize=768%2C512&amp;ssl=1 768w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?resize=1536%2C1024&amp;ssl=1 1536w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?w=2280 2280w" sizes="(max-width: 760px) 100vw, 760px" data-attachment-id="1973" data-permalink="https://danielzickler.com/maximizing-productivity-in-medicine-4-essential-strategies/kiefer-likens-6jwvsegpwom-unsplash#main" data-orig-file="https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?fit=2560%2C1707&amp;ssl=1" data-orig-size="2560,1707" data-comments-opened="1" data-image-title="kiefer-likens-6JwvsEGpWOM-unsplash" data-image-description="&lt;p&gt;Unsplash&lt;/p&gt;
" data-image-caption="&lt;p&gt;Unsplash&lt;/p&gt;
" data-large-file="https://i0.wp.com/danielzickler.com/wp-content/uploads/2024/05/kiefer-likens-6JwvsEGpWOM-unsplash-scaled.jpg?fit=760%2C507&amp;ssl=1" /></a>
<ol>
<li><strong>Effective Time Management</strong>: With numerous responsibilities competing for attention, mastering time management is crucial. Prioritize tasks based on urgency and importance, utilizing tools like to-do lists, calendars, and time-blocking techniques. Allocate specific time slots for patient consultations, administrative duties, and personal development to ensure a balanced workflow.</li>
<li><strong>Utilization of Technology</strong>: Embrace technology to streamline processes and optimize efficiency. Electronic health records (EHRs), telemedicine platforms, and healthcare apps can automate routine tasks, enhance communication among healthcare teams, and facilitate remote consultations. Investing in user-friendly technologies tailored to medical workflows can significantly reduce administrative burden and improve overall productivity.</li>
<li><strong>Continuous Learning and Skill Development</strong>: Medicine is a dynamic field that constantly evolves with new research findings, technologies, and treatment modalities. Stay updated with the latest medical advancements through continuing education, conferences, and online courses. Cultivate a habit of lifelong learning to enhance clinical expertise, critical thinking skills, and problem-solving abilities, ultimately increasing productivity and delivering superior patient care.</li>
<li><strong>Collaborative Teamwork</strong>: Foster a culture of collaboration and teamwork within healthcare settings. Effective communication, delegation, and mutual support among colleagues can streamline workflow processes, enhance decision-making, and prevent burnout. Encourage interdisciplinary collaboration among physicians, nurses, allied healthcare professionals, and administrative staff to leverage diverse expertise and resources for optimal patient outcomes.</li>
</ol>
<p>By implementing these strategies, medical professionals can boost productivity, improve efficiency, and ultimately, deliver better healthcare experiences for patients while maintaining a healthy work-life balance.</p>
<p>&nbsp;</p>
<p>Image: Unsplash</p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/maximizing-productivity-in-medicine-4-essential-strategies/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">1972</post-id>	</item>
		<item>
		<title>Quote Of The Week</title>
		<link>https://danielzickler.com/quote-of-the-week</link>
		<comments>https://danielzickler.com/quote-of-the-week#respond</comments>
		<pubDate>Mon, 16 Sep 2019 19:13:44 +0000</pubDate>
		<dc:creator>Daniel Zickler</dc:creator>
				<category><![CDATA[Career]]></category>
		<category><![CDATA[English]]></category>
		<guid isPermaLink="false">http://danielzickler.com/?p=1704</guid>

				<description><![CDATA[Deliver some love this week!]]></description>
					<content:encoded><![CDATA[<a href="https://danielzickler.com/quote-of-the-week"><img width="760" height="760" src="https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?fit=760%2C760&amp;ssl=1" class="featured-image wp-post-image" alt="" srcset="https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?w=1197&amp;ssl=1 1197w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=150%2C150&amp;ssl=1 150w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=300%2C300&amp;ssl=1 300w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=768%2C768&amp;ssl=1 768w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=1024%2C1024&amp;ssl=1 1024w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=35%2C35&amp;ssl=1 35w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=760%2C760&amp;ssl=1 760w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=400%2C400&amp;ssl=1 400w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=82%2C82&amp;ssl=1 82w, https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?resize=600%2C600&amp;ssl=1 600w" sizes="(max-width: 760px) 100vw, 760px" data-attachment-id="1705" data-permalink="https://danielzickler.com/quote-of-the-week/download#main" data-orig-file="https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?fit=1197%2C1197&amp;ssl=1" data-orig-size="1197,1197" data-comments-opened="1" data-image-title="Download" data-image-description="" data-image-caption="" data-large-file="https://i0.wp.com/danielzickler.com/wp-content/uploads/2019/09/Download.png?fit=760%2C760&amp;ssl=1" /></a><p>Deliver some love this week!</p>]]></content:encoded>
			

		<wfw:commentRss>https://danielzickler.com/quote-of-the-week/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
				<post-id xmlns="com-wordpress:feed-additions:1">1704</post-id>	</item>
	</channel>
</rss>